Lundbeckfond Ventures et al. invest in DySis Medical

The investment is comprised of £6m from Copenhagen-based Lundbeckfond, an investment group specialising in life sciences.

A further £1.4m was raised through existing shareholders Albion Ventures, NBGI and the Scottish Investment Bank (SIB), the investment arm of Scottish Enterprise.

Company
Founded in 2002 and based near Edinburgh, DySis Medical develops and markets the DySis colposcope, which detects early stages of cervical cancer.

The system was recommended for procurement by the UK National Institute for Health and Clinical Excellence in August 2012.

The DySis colposcopy system has a CE mark and has been cleared for use by the US Food and Drugs Administration. With a growing installed base of instruments, an estimated 10,000 women have had a DySis exam to date.

People
Alastair Atkinson is the CEO of DySis. Mikael Strindlund and Casper Breum from Lundbeckfond will join the company's board.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• UK / Ireland
• Healthcare
• Expansion
• Now researching
• United Kingdom
• Albion Ventures
• NBGI Private Equity